The global blood stream infection testing market size was valued at US$ 3,758.7 million in 2017, and is expected to exhibit a CAGR of 8.4% over the forecast period (2019 – 2026).

A bacterial, fungal, or another type of infection identified in the bloodstream is known as a bloodstream infection. When the infection enters the bloodstream of any region of the body, the disease becomes apparent. Bloodstream infection testing is used to identify the bacteria or organisms that cause the blood infection. Human health is at risk because as the human population grows, hygiene levels decline, resulting in the spread of numerous infectious illnesses. According to a 2016 World Bank report, the global population has risen to 7.44 billion people. As the world's population grows, so does the market for blood-stream infection diagnostics. Because bloodstream infections are so widespread, self-diagnosis is difficult.

The bloodstream infection testing market is predicted to develop due to the rising prevalence of abdominal infection, dental infection, and chronic disorders.

Disease transmission is primarily caused by overcrowding and a lack of adequate shelter. Furthermore, rising awareness of chronic diseases such as cancer, HIV, and pneumonia, which necessitate blood testing at regular intervals, is likely to drive market expansion. The expansion of the bloodstream infection testing market is aided by innovations, R&D investments, and important vendor mergers and acquisitions.

The market is expected to develop due to the geographic expansion of bloodstream infection testing manufacturers into North America.

The global Blood Stream Infection Testing Market is divided into North America, Europe, Latin America, Asia Pacific, the Middle East, and Africa based on region. Because of increased preventative healthcare awareness and the high adoption of novel technologies, North America dominated the worldwide bloodstream infection testing market in 2018. In addition, the region's high diagnosis rate and established medical facilities fuel the growth of the bloodstream infection testing market in North America.

Players to Watch

BioMérieux SA, Becton, Dickinson and Company, AB Sciex, IRIDICA, Abbot Laboratories, Cepheid Inc., C. R. Bard, Inc., F. Hoffmann-La Roche AG, Nanosphere, Dade Behring, AdvanDX, and Siemens Healthcare are among the major participants in the blood stream infection testing industry.